Triple-Negative Breast Carcinoma — Trials

Triple-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 417
Recruiting: 234
Ph III recruiting: 22
Growth YoY: +2.4%
Industry share: 31%
Top sponsor: Fudan University
Termination share: 47.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 51–66 of 66 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02978716	Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)	terminated	Phase 2	102	G1 Therapeutics, Inc.INDUSTRY	8	Mar 23, 2022	clinicaltrials
NCT03733119	ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer	terminated	Phase 2	4	University of Wisconsin, MadisonOTHER	1	Mar 10, 2022	clinicaltrials